Prescribers Should Restrict the Use of Non-FDA-Approved Compounded Bioidentical Hormones, Except for Specific Medical Circumstances

The use of compounded bioidentical hormone therapies (cBHTs) — an increasingly preferred technique to reduce indicators of menopause and male hypogonadism — must be confined to the smaller range of people who are not able to reward from an Fda-authorized hormone therapy products, says a new report from the Nationwide Academies of Sciences, Engineering, and Medication.